Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers.

Chiquette E, Toth PP, Ramirez G, Cobble M, Chilton R

Vascular health and risk management12 Nov 2012Cited by 42 (Europe PMC)

PMID23166441PMCIDPMC3500143DOI10.2147/vhrm.s37969PepBankPUB-23166441

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, both weekly and twice-daily exenatide reduced triglycerides.
In plain wordsIn patients with type 2 diabetes, both weekly and twice-daily exenatide reduced triglycerides.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTriglycerides
Study
n = 211
Outcome group
Lipids · Cardiovascular
Studied dose
once weekly and twice daily · 30 weeksAs given in this study (human).
Source sentences
Summary
Triglycerides, very low-density lipoprotein cholesterol, and high sensitivity C-reactive protein were reduced with both the once-weekly and twice-daily exenatide regimens (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In the DURATION-1 trial, patients with type 2 diabetes were treated with exenatide once weekly or twice daily for 30 weeks.
Summary · context
This post hoc analysis evaluated the impact of exenatide on lipoprotein subclasses in 211 DURATION-1 patients using vertical auto profile methodology and the Statistical Package for the Social Sciences general linear model adjusted for glycosylated hemoglobin (HbA(1c)) and weight.
Report a problemFND-2316644105
02HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, both weekly and twice-daily exenatide reduced VLDL cholesterol.
In plain wordsIn patients with type 2 diabetes, both weekly and twice-daily exenatide reduced VLDL cholesterol.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseVLDL cholesterol
Study
n = 211
Outcome group
Lipids · Cardiovascular
Studied dose
once weekly and twice daily · 30 weeksAs given in this study (human).
Source sentences
Summary
Triglycerides, very low-density lipoprotein cholesterol, and high sensitivity C-reactive protein were reduced with both the once-weekly and twice-daily exenatide regimens (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In the DURATION-1 trial, patients with type 2 diabetes were treated with exenatide once weekly or twice daily for 30 weeks.
Summary · context
This post hoc analysis evaluated the impact of exenatide on lipoprotein subclasses in 211 DURATION-1 patients using vertical auto profile methodology and the Statistical Package for the Social Sciences general linear model adjusted for glycosylated hemoglobin (HbA(1c)) and weight.
Report a problemFND-2316644106
03HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, both weekly and twice-daily exenatide reduced high sensitivity C-reactive protein.
In plain wordsIn patients with type 2 diabetes, both weekly and twice-daily exenatide reduced the inflammation marker C-reactive protein.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHigh sensitivity C-reactive protein
Study
n = 211
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
once weekly and twice daily · 30 weeksAs given in this study (human).
Source sentences
Summary
Triglycerides, very low-density lipoprotein cholesterol, and high sensitivity C-reactive protein were reduced with both the once-weekly and twice-daily exenatide regimens (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In the DURATION-1 trial, patients with type 2 diabetes were treated with exenatide once weekly or twice daily for 30 weeks.
Summary · context
This post hoc analysis evaluated the impact of exenatide on lipoprotein subclasses in 211 DURATION-1 patients using vertical auto profile methodology and the Statistical Package for the Social Sciences general linear model adjusted for glycosylated hemoglobin (HbA(1c)) and weight.
Report a problemFND-2316644107
04HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, weekly exenatide reduced apolipoprotein B independently of glycemic improvement and weight loss.
In plain wordsIn patients with type 2 diabetes, weekly exenatide reduced apolipoprotein B independently of blood sugar improvement and weight loss.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseApolipoprotein B
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Studied dose
once weekly · 30 weeksAs given in this study (human).
Source sentences
Summary
Once-weekly exenatide reduced apolipoprotein B and the apolipoprotein B to apolipoprotein A1 ratio (P < 0.05), independent of glycemic improvement and weight loss.
2 context sentences(design, population, supporting numbers)
Summary · context
In the DURATION-1 trial, patients with type 2 diabetes were treated with exenatide once weekly or twice daily for 30 weeks.
Summary · context
This post hoc analysis evaluated the impact of exenatide on lipoprotein subclasses in 211 DURATION-1 patients using vertical auto profile methodology and the Statistical Package for the Social Sciences general linear model adjusted for glycosylated hemoglobin (HbA(1c)) and weight.
Report a problemFND-2316644101
05HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, weekly exenatide reduced the apolipoprotein B to A1 ratio independently of glycemic improvement and weight loss.
In plain wordsIn patients with type 2 diabetes, weekly exenatide reduced the apolipoprotein B to A1 ratio independently of sugar improvement and weight loss.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseApolipoprotein B to A1 ratio
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Studied dose
once weekly · 30 weeksAs given in this study (human).
Source sentences
Summary
Once-weekly exenatide reduced apolipoprotein B and the apolipoprotein B to apolipoprotein A1 ratio (P < 0.05), independent of glycemic improvement and weight loss.
2 context sentences(design, population, supporting numbers)
Summary · context
In the DURATION-1 trial, patients with type 2 diabetes were treated with exenatide once weekly or twice daily for 30 weeks.
Summary · context
This post hoc analysis evaluated the impact of exenatide on lipoprotein subclasses in 211 DURATION-1 patients using vertical auto profile methodology and the Statistical Package for the Social Sciences general linear model adjusted for glycosylated hemoglobin (HbA(1c)) and weight.
Report a problemFND-2316644102
06HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes receiving exenatide, lipoprotein patterns shifted away from small, dense LDL-4 cholesterol.
In plain wordsIn patients with type 2 diabetes receiving exenatide, the cholesterol pattern shifted away from small, dense LDL particles.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSmall dense LDL-4 lipoprotein pattern
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Source sentences
Summary
A significant shift in lipoprotein pattern away from small, dense low-density lipoprotein-4 cholesterol was also observed (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In the DURATION-1 trial, patients with type 2 diabetes were treated with exenatide once weekly or twice daily for 30 weeks.
Summary · context
This post hoc analysis evaluated the impact of exenatide on lipoprotein subclasses in 211 DURATION-1 patients using vertical auto profile methodology and the Statistical Package for the Social Sciences general linear model adjusted for glycosylated hemoglobin (HbA(1c)) and weight.
Report a problemFND-2316644103
07HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, weekly exenatide increased HDL-2 cholesterol after adjustment for HbA1c and weight changes.
In plain wordsIn patients with type 2 diabetes, weekly exenatide increased HDL-2 cholesterol after accounting for blood sugar and weight changes.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHDL-2 cholesterol
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Studied dose
once weekly · 30 weeksAs given in this study (human).
Source sentences
Summary
Exenatide once weekly increased high-density lipoprotein-2 cholesterol, even after adjustment for changes in HbA(1c) and weight (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In the DURATION-1 trial, patients with type 2 diabetes were treated with exenatide once weekly or twice daily for 30 weeks.
Summary · context
This post hoc analysis evaluated the impact of exenatide on lipoprotein subclasses in 211 DURATION-1 patients using vertical auto profile methodology and the Statistical Package for the Social Sciences general linear model adjusted for glycosylated hemoglobin (HbA(1c)) and weight.
Report a problemFND-2316644104

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00308139

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

AstraZenecan = 303Apr 2006 to Aug 2014

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 26 Aug 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.